Onsior or Robenacoxib is a nonsteroidal anti-inflammatory drug [NSAID] that effectively relieves acute pain and post soft-tissue surgery and inflammation in cats. It travels rapidly through the bloodstream to selectively target the tissues involved in inflammation and pain. The drug takes effect and exits the blood quickly, to reduce potential side effects. Causes fewer gastrointestinal side effects by selective inhibition of prostaglandin formation.Add this item to your cart:
**Note: This product requires a veterinarian's prescription to purchase.At checkout you will need to provide your veterinarian's FAX or email address. We will then send him or her a prescription verification that he or she will need to sign and return before we can ship you this product.
Dosage and Administration:
It is important to follow your Veterinarian's prescription dosage, precautions and instructions.
The typical dose of ONSIOR tablets is 0.45 mg/lb 1 mg/kg orally once daily, for a maximum of three days.
For oral use in cats 5.5 lbs/&above and 6 months of age/& above for up to a maximum of 3 days.
Tablets are not scored and should not be broken.
Body weight 6 mg ONSIOR Tablet
5.5 to 13.2 lbs 2.5 to 6 kg 1 whole tablet once daily
13.3 to 26.4 lbs 6.1 to 12 kg 2 whole tablets once daily
The first dose should be administered approximately 30 minutes prior to surgery, at the same time as the pre-anesthetic agents are given.
ONSIOR tablets may be given with or without food.
ONSIOR tablets should not be used in cats that have a hypersensitivity to robenacoxib or known intolerance to NSAIDs.
Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For use in cats only. All cats should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory tests should be conducted to establish hematological and serum biochemical baseline data prior to administration of an NSAID. Owners should be advised to observe for signs of potential drug toxicity.
Do not administer ONSIOR tablets in conjunction with any other oral or injectable NSAID or corticosteroid.
Appetite should be monitored in cats receiving ONSIOR tablets. Stop administration of ONSIOR tablets if appetite decreases. The use of ONSIOR tablets has not been evaluated in cats younger than 6 months of age, cats weighing less than 5.5 lbs, cats used for breeding, or in pregnant or lactating cats. The use of ONSIOR tablets in cats with cardiac disease has not been studied. ONSIOR tablets has been shown to prolong the QT interval in a laboratory setting. As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal, and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Cats that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for adverse events are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Anesthetic drugs may affect renal perfusion approach concomitant use of anesthetics and NSAIDs cautiously. Appropriate monitoring procedures including ECG should be employed during all surgical procedures. The use of parenteral fluids during surgery is recommended to decrease potential renal complications when using NSAIDs perioperatively. If additional pain medication is needed after a daily dose of ONSIOR tablets, a non-NSAID/non-corticosteroid class of analgesic may be necessary. Concurrent administration of potentially nephrotoxic drugs should be carefully approached and monitored. NSAIDs may inhibit prostaglandins which maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. NSAIDs possess the potential to produce gastrointestinal ulcerations and/or gastrointestinal perforations. Do not use ONSIOR tablets concomitantly with other anti-inflammatory drugs, such as NSAIDs or corticosteroids. Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use. The use of concomitantly protein-bound drugs with ONSIOR tablets has not been studied in cats. Commonly used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of ONSIOR tablets has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy. Concurrent medications used during the field study with ONSIOR tablets included antiparasiticides, anesthetics, pre-anesthetic medications, and antibiotics. The effect of cyclo-oxygenase inhibition and the potential for thromboembolic occurrence or a hypercoagulable state has not been evaluated. It is unknown whether cats with a history of hypersensitivity to &beta lactam drugs will exhibit hypersensitivity to ONSIOR tablets. Robenacoxib is poorly soluble in water and in acid solutions readily degrades to form &gamma-lactam. In cats, lactam is a metabolite of robenacoxib. Additionally, lactam is a degradation product that increases over the shelf-life of the tablets. Neurologic signs have been associated with the use of &beta lactam drugs it is unknown if the lactam in robenacoxib may cause similar neurologic signs See Animal Safety. Robenacoxib may prolong the QT interval the associated risk of developing ventricular arrhythmia is unknown. The use of robenacoxib with other drugs shown to prolong the QT interval is not recommended. Commonly used drugs that prolong the QT interval include antihistamines and prokinetic drugs. Adverse Reactions: In a controlled field study, a total of 249 male and female cats representing 6 breeds, 6 months to 13 years old, weighing 5.5 - 15 lbs were included in the field safety analysis. The following table shows the number of cats exhibiting each observation. Adverse Reactions in the Postoperative Pain Field Study1 Clinical Sign ONSIOR 6 mg Tablets for Cats robenacoxib n = 167 Placebo vehicle control n = 82 Inappetance, weight loss 4 2 Incision site bleeding 7 1 Incision site infection 6 2 Decreased activity, lethargy 4 1 Cystitis, hematuria 3 0 Hair loss, excoriation, bruising 2 0 Vomiting 4 1 Hematachezia, diarrhea 3 1 Respiratory, cardiac arrest 1 0 Incoordination, weakness 1 1 Death 0 1 1Cats may have experienced more than one of these signs during the study. The most commonly reported adverse reactions were surgical site bleeding, infected surgery sites, lethargy, vomiting and inappetance. Changes in the clinical pathology values were not considered clinically significant. To report suspected adverse drug events, contact Novartis Animal Health at 1-800-332-2761 or the FDA at 1-800-FDA-VETS or http://www.fda. gov/AnimalVeterinary/SafetyHealth/ReportaProblem/ucm055305.htm. For technical assistance, contact Novartis Animal Health at 1-800-332-2761.
Information for Cat Owners:
ONSIOR tablets, like other drugs of its class, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance. Adverse reactions may include vomiting, diarrhea, decreased appetite, dark or tarry stools, increased water consumption, increased urination, anemia, yellowing of gums, skin or white of the eye due to jaundice, lethargy, incoordination, seizure, or behavioral changes. Serious adverse reactions associated with this drug class can occur without warning and in rare situations result in death see Warnings and Adverse Reactions. Owners should be advised to discontinue ONSIOR tablets and contact their veterinarian immediately if signs of intolerance are observed. The vast majority of patients with drug related adverse reactions have recovered when the signs are recognized, the drug is withdrawn, and veterinary care, if appropriate, is initiated.
Store at controlled room temperature, between 59° and 77°F 15-25°C. Manufactured for: Novartis Animal Health US, Inc., Greensboro, NC 27408 USA